Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology
Dr. Robert Langer and his son Michael Langer have launched T.Rx Capital, a venture capital firm focused on investing in startups operating at the intersection of technology and biology379.
T.Rx Capital Fund I has been launched with $77.5 million in committed capital to target bold, early-stage companies that combine cutting-edge biology and technology1359.
The Langer family is leveraging expertise from Robert Langer’s legacy in biotech (as a Moderna co-founder) and Michael Langer’s experience in investment to guide T.Rx Capital’s strategy357.
The fund is specifically focused on creation, seed, and Series A rounds, with the goal of supporting disruptive innovation in healthcare and biotechnology7.
The launch of T.Rx Capital Fund I was announced on September 18-19, 2025, marking a high-profile entry by the Langer family into dedicated biotech-tech venture capital investing1359.
Sources:
1. https://www.pharmiweb.com/press-release/2025-09-18/trx-capital-launches-775m-fund-i-to-invest-in-bold-startups-at-the-intersection-of-technology-and
3. https://www.axios.com/pro/biotech-deals/2025/09/18/trx-capital-launches-with-77m-fund
5. https://www.businesswire.com/news/home/20250918207420/en/T.Rx-Capital-Launches-$77.5M-Fund-I-to-Invest-in-Bold-Startups-at-the-Intersection-of-Technology-and-Biology